• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
MIAO Yiting,GE Yalong,HUANG Jing,HE Xuemei,ZHAO Xuan,CHAI Chengcheng,JIANG Dongyang,LIANG Ying.Meta-analysis of sacubitril-valsartan versus renin-angiotensin-aldosterone system inhibitors in the treatment of elderly refractory heart failure[J].Journal Of Pharmaceutical Research,2024,43(4):402-408[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3074times   Download 3067次 QR Code for this article
Scan with your phone!
沙库巴曲缬沙坦治疗老年顽固性心力衰竭疗效优势的Meta分析
苗依婷1,2,葛亚龙3,黄晶2,贺雪梅2,赵萱2,4,柴程程2,蒋东洋2,梁英2
Font:Larger+|Default|Smaller-
(1.山东第二医科大学临床医学院,山东 潍坊 261000;2.山东第一医科大学第一附属医院<山东省千佛山医院>全科医学科,山东 济南 250014;3.济南市第三人民医院心血管内科,山东 济南 250132;4.济宁医学院临床医学院,山东 济宁 272013)
摘要:
目的 系统评价沙库巴曲缬沙坦(ARNI)对比肾素-血管紧张素-醛固酮系统(RAAS)抑制剂(ACEI/ARB)在治疗老年顽固性心力衰竭(RHF)患者的疗效和安全性。方法 检索英文数据库(Pubmed、Embase、Web of science、the Conchrane Library)及中文数据库(知网、万方、维普、CBM)中已发表的随机对照试验(RCTs),采用Cochrane风险评估工具对文献质量进行评价,采用RevMan及Stata软件进行Meta分析。结果 纳入10篇文献共1 118例老年RHF患者。结果显示,应用ARNI组(研究组)氨基末端脑钠尿肽前体(NT-proBNP)(MD=-282.61,95%CI -344.56 ~ -220.66,P﹤0.05)、左心室舒张末期内径(LVEDD)(MD=-3.48,95%CI -4.58 ~ -2.39,P﹤0.05)低于应用ACEI/ARB组(对照组);左心室射血分数(LVEF)(MD=6.35,95%CI 4.65 ~ 8.06,P﹤0.05)、有效率(OR=2.449,95%CI 1.851~ 3.241,P﹤0.05)明显高于对照组。两组肾功能损害、头晕、高血钾比较无差异,低血压发生率低于对照组。结论 与ACEI/ARB相比,ARNI可显著改善心室重构,进一步改善老年RHF患者心功能,并且安全性良好。
关键词:  顽固性心力衰竭  老年  沙库巴曲缬沙坦  肾素-血管紧张素-醛固酮系统抑制剂  Meta分析
DOI:10.13506/j.cnki.jpr.2024.04.016
基金项目:
Publication Date:April 25, 2024
Meta-analysis of sacubitril-valsartan versus renin-angiotensin-aldosterone system inhibitors in the treatment of elderly refractory heart failure
MIAO Yiting1,2,GE Yalong3,HUANG Jing2,HE Xuemei2,ZHAO Xuan2,4,CHAI Chengcheng2,JIANG Dongyang2,LIANG Ying2
(1.School of Clinical Medicine, Shandong Second Medical University, Weifang 261000,China;2.Department of General Practice,the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,Jinan 250014,China;3.Department of Cardiovascular,Jinan Third Hospital, Jinan 250101,China;4.School of Clinical Medicine, Jining Medical University,Jining 272013,China)
Abstract:
Objective To systematically evaluate the efficacy and safety of sacubitril-valsartan(ARNI) compared to angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists(ACEI/ARB)in the treatment of elderly refractory heart failure patients.Methods The literatures were obtained in The Cochrane Library, Embase, PubMed, Web of science and Chinese databases (CNKI, VIP ,WanFang and CBM). After literature screening and data extraction, the quality of the included literature was evaluated using the Cochrane bias risk assessment tool. Meta analysis was conducted using RevMan and Stata software.Results A total of 10 literatures were included, with a total of 1 118 elderly refractory heart failure patients including. Meta-analysis results showed that the N-terminal proBNP(NT-proBNP)(MD=-282.61,95%CI -344.56~ -220.66,P﹤0.05), the left ventricular end-diastolic diameter(LVEDD)(MD=-3.48,95%CI -4.58~ -2.39,P﹤0.05) in the study group were lower than those in the control group; the left ventricular ejection fraction (LVEF)(MD=6.13, 95%CI 5.15~7.11, P<0.05) and effective rate (OR=2.548, 95%CI 2.058~3.154, P<0.05) were significantly higher than those in the control group, respectively. The left ventricular ejection fraction (LVEF) (MD=6.35,95%CI 4.65~8.06,P﹤0.05) and effective rate (OR=2.449,95%CI 1.851—3.241,P﹤0.05) were significantly higher than those in the control group. In terms of adverse reactions, there was no difference in renal function damage, dizzy and hyperkalemia between the two groups, and the incidence of hypotension in the study group was lower than that in the control group.Conclusion Compared with ACEI/ARB, sacubitril-valsartan can significantly improve cardiac function, improve ventricular remodeling, and reduce myocardial tissue damage in elderly patients with refractory heart failure without significant adverse reactions.
Key words:  Refractory Heart Failure  elderly  sacubitril-valsartan  renin-angiotensin-aldosterone system inhibitors  Meta-analysis
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.